Big Pharma’s Rap Sheet
It was one of those conversations you never forget. We were discussing—of all things—the Covid injections, and I was questioning the early ‘safe and effective’ claims put forward by the pharmaceutical industry. I felt suspicious of how quickly we had arrived at that point of seeming consensus despite a lack of long-term safety data. I […]
CDC Narrows RSV Vaccine Guidelines Due to Safety Concerns
The U.S. Centers for Disease Control and Prevention (CDC) has recently narrowed its original recommendations for the respiratory syncytial virus (RSV) vaccine, citing concerns over the risk of a side effect that can lead to paralysis or death. The recommendations originally stated adults over the age of 60 should receive the vaccine, but updates in […]
Vaccines, Doses & Shots. Confused?
In a phone conversation with Robert F. Kennedy, Jr. regarding childhood vaccinations last month, Donald Trump said: When you feed a baby, Bobby, a vaccination that is, like, 38 different vaccines and it looks like it’s been for a horse. Not a, you know, 10-pound or 20-pound baby. And then you see the baby all […]
Appellate Court Tosses Out 1,200 Shingles Vaccine Injury Lawsuits Against Merck
The Third Circuit U.S. Court of Appeals dismissed approximately 1,200 lawsuits filed against Merck & Co. over its shingles vaccine, Zostavax. The Appellate Court upheld a U.S. District Court ruling that threw out the lawsuits for failing to abide by a court order requiring them to provide clinical test results.1 Zostavax, the first shingles vaccine […]
Novel Breast Cancer Vaccine Technology Receives Japanese Patent
Anixa Biosciences, Inc. of San Jose, California announced on July 17, 2024, that its collaborator, the Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Vaccine Adjuvants and Formulations” for its novel breast cancer vaccine technology. The company is two decades into developing a […]
Guillain-Barré Syndrome ‘More Common Than Expected’ in Early RSV Vaccine Trial
Reports of the nervous system disorder Guillain-Barré syndrome (GBS) were “more common than expected” in the older adult population who received the new vaccine for respiratory syncytial virus (RSV). The data, reported by the U.S. Centers for Disease Control and Prevention (CDC), matched trial data reported earlier this year.1 GBS is a “polio-like” inflammatory autoimmune […]
